391 related articles for article (PubMed ID: 12737635)
21. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments.
Luo N; Johnson J; Coons SJ
Med Care; 2010 Apr; 48(4):365-71. PubMed ID: 20355266
[TBL] [Abstract][Full Text] [Related]
22. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
23. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
24. Predicting preference-based SF-6D index scores from the SF-8 health survey.
Wang P; Fu AZ; Wee HL; Lee J; Tai ES; Thumboo J; Luo N
Qual Life Res; 2013 Sep; 22(7):1675-83. PubMed ID: 23054496
[TBL] [Abstract][Full Text] [Related]
25. Psychometric Performance of the SF-6D Quality of Life Measure in an Outpatient Population with Bipolar Disorder.
Pogue YZ; Lavelle TA; Hodgkin D; Sylvia L; Ritter G; Nierenberg A
J Ment Health Policy Econ; 2022 Dec; 25(4):143-150. PubMed ID: 36535912
[TBL] [Abstract][Full Text] [Related]
26. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis.
Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N
Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661
[TBL] [Abstract][Full Text] [Related]
27. Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries.
Dawoud DM; El-Dahiyat F; Abojedi A; Dawoud N; Soliman AM; Hussein M; Mohamed O; Hasan SS; Babar ZU; Kharroubi SA
Res Social Adm Pharm; 2020 Dec; 16(12):1754-1759. PubMed ID: 32057690
[TBL] [Abstract][Full Text] [Related]
28. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD).
Chen J; Wong CK; McGhee SM; Pang PK; Yu WC
PLoS One; 2014; 9(11):e112389. PubMed ID: 25379673
[TBL] [Abstract][Full Text] [Related]
29. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
Whitehurst DG; Norman R; Brazier JE; Viney R
Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
[TBL] [Abstract][Full Text] [Related]
30. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?
Boonen A; van der Heijde D; Landewé R; van Tubergen A; Mielants H; Dougados M; van der Linden S
Ann Rheum Dis; 2007 Jun; 66(6):771-7. PubMed ID: 17213254
[TBL] [Abstract][Full Text] [Related]
31. Comparing short form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients.
Feeny D; Wu L; Eng K
Qual Life Res; 2004 Dec; 13(10):1659-70. PubMed ID: 15651537
[TBL] [Abstract][Full Text] [Related]
32. The relationship between SF-6D utility scores and lifestyle factors across three life stages: evidence from the Australian Longitudinal Study on Women's Health.
Kanesarajah J; Waller M; Whitty JA; Mishra GD
Qual Life Res; 2017 Jun; 26(6):1507-1519. PubMed ID: 28155049
[TBL] [Abstract][Full Text] [Related]
33. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
[TBL] [Abstract][Full Text] [Related]
34. Comparison of health-related quality of life and functional recovery measurement tools in out-of-hospital cardiac arrest survivors.
Andrew E; Nehme Z; Bernard S; Smith K
Resuscitation; 2016 Oct; 107():57-64. PubMed ID: 27521474
[TBL] [Abstract][Full Text] [Related]
35. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
[TBL] [Abstract][Full Text] [Related]
36. Valuing postoperative recovery: validation of the SF-6D health-state utility.
Lee L; Elfassy N; Li C; Latimer E; Liberman AS; Charlebois P; Stein B; Carli F; Fried GM; Feldman LS
J Surg Res; 2013 Sep; 184(1):108-14. PubMed ID: 23522456
[TBL] [Abstract][Full Text] [Related]
37. The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36.
Colangelo KJ; Pope JE; Peschken C
J Rheumatol; 2009 Oct; 36(10):2231-7. PubMed ID: 19723907
[TBL] [Abstract][Full Text] [Related]
38. Unchained melody: revisiting the estimation of SF-6D values.
Craig BM
Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
[TBL] [Abstract][Full Text] [Related]
39. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
40. Mapping of the Gastrointestinal Short Form Questionnaire (GSF-Q) into EQ-5D-3L and SF-6D in patients with gastroesophageal reflux disease.
Monroy M; Ruiz MA; Rejas J; Soto J
Health Qual Life Outcomes; 2018 Sep; 16(1):177. PubMed ID: 30200982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
